Congress 2014 has ended
Back To Schedule
Thursday, May 1 • 12:45pm - 1:45pm
Treatment Considerations for Chronic Myeloid Leukemia (CML) Adult Patients After Multiple Tyrosine Kinase Inhibitor (TKI) Failures

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

With the approval and launch of five oral tyrosine kinase inhibitors (TKIs) and one SQ protein synthesis inhibitor—as well as learnings and improvements in monitoring the disease—chronic myeloid leukemia (CML) has steadily transformed to an ever more chronic disease. This theater presentation will provide an overview of CML that will include the basics of the disease, with a focus on the management of patients in whom at least two TKIs have failed. It will review and discuss a relevant CML patient case and associated course of treatment.

This is a Teva Oncology promotional activity. Seating is on a first-come, first-served basis. Please plan to arrive early to have the best chance at securing your seat. 

Thursday May 1, 2014 12:45pm - 1:45pm PDT
Theater 1, Hall B Anaheim Convention Center, 800 W. Katella Avenue. Anaheim, CA 92802
  Industry Event
  • CNE Status No CNE
  • Contact Hours of CNE: N/A

Attendees (0)